Semaglutide extended lifespan and slowed several signs of aging in older female mice in research published in September 2026. The study, reported in Nature and funded in part by the National Institutes of Health, adds a surprising possibility to the growing list of effects linked to GLP-1 drugs: they may influence biological aging itself.
Researchers at the University of California, Berkeley treated 20-month-old female mice with semaglutide, a GLP-1 receptor agonist already used for diabetes and obesity. After three months, the animals showed better physical function and changes in several biological processes associated with aging. Continued treatment also extended lifespan. These findings are important, but they do not show that the same longevity effect occurs in people.
Why Would a Metabolic Drug Affect Aging?
GLP-1 medicines influence appetite, blood sugar and energy metabolism. These systems are closely connected with conditions that become more common with age, including cardiovascular disease, obesity and type 2 diabetes.
The National Institutes of Health reports that semaglutide appeared to reproduce several effects associated with calorie restriction in the mouse study. Calorie restriction has extended lifespan in multiple animal models, although translating those findings into practical human longevity treatments remains difficult.
Researchers also found changes involving nutrient-sensing pathways and genetic regulators associated with aging. Some functional improvements went beyond those seen with calorie restriction, including differences in glucose control, memory and exploratory behavior.
Promising Mice Are Still Mice
The distinction between animal and human evidence is critical. The experiment involved older female mice of a specific laboratory strain. Human aging is far more complicated, and people may take GLP-1 medicines for years while living with different diseases, diets and lifestyles.
Human research nevertheless provides reasons for continued investigation. A 2026 analysis highlighted by Yale School of Medicine found that some pharmacological interventions, including semaglutide and metformin, were associated with reductions in measures of epigenetic age. However, epigenetic clocks are biomarkers. A younger reading does not prove that a person will live longer.
Where Do Exercise and Diet Fit?
Established lifestyle measures still have a much broader human evidence base. A 2026 systematic review and meta-analysis published in The Lancet Healthy Longevity found that higher physical activity was associated with lower biological age on some DNA methylation measures. The authors also cautioned that much of the evidence was observational.
Nutrition remains important too. A review in the Annual Review of Nutrition found evidence connecting calorie restriction, Mediterranean-style diets and other nutritional strategies with certain biological-age markers, while emphasizing major challenges in translating biomarkers into longer life.
Why GLP-1 Research Is Expanding
Scientists are increasingly interested in GLP-1 drugs because their effects appear to reach beyond body weight. Better metabolic control, lower disease risk and changes in pathways related to aging could help explain why researchers are examining these medicines in a wider range of conditions.
The new mouse findings make longevity another intriguing research direction. They are not evidence that semaglutide should be prescribed as an anti-aging treatment. For now, the study provides something more useful scientifically: a new clue about how metabolism and the aging process may be connected.
